Navigation Links
Encision Inc. and Virtual Ports Ltd. Announce Exclusive Distribution Agreement for Laparoscopic Surgery Devices

BOULDER, Colo., April 16, 2013 /PRNewswire/ -- Encision Inc. ("Encision") (ECIA: PK) is pleased to announce an agreement with Virtual Ports Ltd. ("Virtual Ports") for exclusive distribution rights to the Virtual Ports' laparoscopic organ retraction products in the United States. Under the terms of the agreement, Encision will market and sell Virtual Ports' organ retraction products. Encision and Virtual Ports are both innovative companies that develop, manufacture and market medical devices that bring a higher level of performance to laparoscopic surgery. Encision's AEM® Technology eliminates stray energy burns during laparoscopic surgery. Virtual Ports' products provide secure laparoscopic organ retraction through its proprietary MicroAnchoring™ Technology.

"We are thrilled to expand our product offerings with Virtual Ports' unique products," said Fred Perner , President and CEO of Encision. "We see this relationship as accelerating our efforts to bring true innovation and improved economic outcomes to laparoscopic procedures. Additionally, Micro-Anchoring Technology aligns perfectly with our targeted audience of laparoscopic surgeons."

Dan Shwarzman , CEO of Virtual Ports, notes, "We are extremely pleased to partner with a focused and innovative company such as Encision to sell and distribute our products. This agreement dramatically expands our reach throughout the U.S. and creates an ideal product synergy with Encision's product line. We look forward to a successful collaboration with Encision and are confident that together we can offer surgeons and patients in the U.S. a new performance standard for laparoscopic surgery."

Virtual Ports Products

Virtual Ports products, including the EndoGrab™ and the EndoLift™, are exceptionally small-profile devices that provide secure laparoscopic organ retraction by using Virtual Port's proprietary MicroAnchoring™ Technology. The EndoGrab™ allows surgeons to retract internal organs and to anchor them directly to the endocavity wall. This retraction moves organs outside of the surgeon's critical view, which results in enhanced tissue access without cluttering the laparoscopic workspace, and reduces the number of ports, incisions and personnel required to perform the procedure. The EndoLift™ is designed specifically to internally retract large, soft tissue structures, such as the liver and uterus, from within the abdominal cavity, which eliminates incisions solely dedicated for retraction.

About Encision

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, Encision pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.  For more information, visit Encision's web site at

About Virtual Ports

Virtual Ports develops, manufactures, and markets medical devices for use in laparoscopic surgery. Its proprietary MicroAnchoring™ Technology provides secure laparoscopic organ retraction using exceptionally small-profile devices. Virtual Ports, started in the Misgav Venture Accelerator in Israel, was established in 2006, and began marketing its products three years ago. Its customers include leading hospitals and medical centers throughout the world. For more information, visit Virtual Port's web site at

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2012 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600,


SOURCE Encision Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Encision Reports First Quarter of Fiscal Year 2013 Results
2. Encision Reports Second Quarter of Fiscal Year 2013 Results
3. Encision Reports 10% Product Revenue Increase in Third Quarter of Fiscal Year 2013 Results
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. LHA Life Sciences & Medical Technologies Virtual Conference
6. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
7. VirtualScopics Schedules Second Quarter 2012 Earnings Announcement
8. FDAnews Announces Medical Device Mobile Apps Virtual Conference
9. VirtualScopics Reports 2nd Quarter 2012 Results
10. Express Scripts Launches Virtual Coaching To Help Patients Better Understand Therapy
11. Sentara Healthcare, MDLIVE Forge Unique Equity Partnership in Virtual Medicine
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology:
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
Breaking Medicine News(10 mins):